Celecoxib for colorectal adenomas increased CV eventsCardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80.SolomonSDMcMurrayJJPfefferMAet alCardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.N Engl J Med20053521071-80Q In patients with a history of colorectal neoplasia who are at risk of recurrent adenomatous polyps, how safe is celecoxib with respect to cardiovascular (CV) events?

For correspondence: Dr S D Solomon, Brigham and Women’s Hospital, Boston, MA, USA. [email protected]

Sources of funding: National Cancer Institute and Pfizer.